Manganese’s Potential Benefits for Diabetic Nerve Health

Diabetes affects nearly 537 million adults worldwide, and up to half of them will develop some form of diabetic neuropathy — a debilitating condition characterized by nerve damage that often leads to chronic pain, numbness, tingling, and muscle weakness. While tight glucose control remains the cornerstone of prevention and management, researchers are increasingly exploring the role of specific micronutrients in protecting peripheral nerves. One such nutrient gaining attention is manganese, a trace mineral that serves as a cofactor for numerous enzymes involved in antioxidant defense, metabolism, and tissue repair. This article examines the current evidence linking manganese to diabetic nerve health, its mechanisms of action, dietary sources, and considerations for supplementation.

Understanding Diabetic Neuropathy

Pathophysiology of Nerve Damage in Diabetes

Diabetic neuropathy arises from a combination of metabolic and vascular insults. Chronic hyperglycemia triggers several biochemical pathways: increased polyol pathway flux, accumulation of advanced glycation end products (AGEs), activation of protein kinase C, and heightened oxidative stress. These processes damage the myelin sheath, impair axonal transport, and induce microvascular ischemia in nerve fibers. The result is progressive loss of sensory, motor, and autonomic nerve function, most commonly manifesting as a symmetrical polyneuropathy in the feet and hands. The condition often begins insidiously, with patients reporting a pins-and-needles sensation that gradually intensifies and spreads proximally.

The Central Role of Oxidative Stress

Oxidative stress is a unifying mechanism in diabetic neuropathy. Excess glucose overloads the mitochondrial electron transport chain, generating superoxide radicals. Reactive oxygen species (ROS) then attack lipids, proteins, and DNA in Schwann cells and neurons, leading to apoptosis and demyelination. Endogenous antioxidant systems — including enzymes like superoxide dismutase (SOD), catalase, and glutathione peroxidase — are often overwhelmed in diabetes. This imbalance creates a vicious cycle where ROS further impair insulin signaling and worsen hyperglycemia. Therefore, nutrients that bolster antioxidant capacity may offer neuroprotection. Among these, manganese stands out because of its exclusive role in mitochondrial SOD, the first line of defense against superoxide in the energy powerhouse of the cell.

Epidemiology and Clinical Impact

Diabetic neuropathy affects approximately 50% of people with diabetes over their lifetime, with incidence rising with disease duration and poor glycemic control. It is a leading cause of non-traumatic lower limb amputations and significantly impairs quality of life due to chronic pain, sleep disturbances, and mobility limitations. The economic burden is substantial, with direct medical costs for neuropathy-related care exceeding billions annually in the United States alone. Given the limited efficacy of current pharmacological treatments — which often provide only partial symptom relief with notable side effects — there is growing interest in adjunctive nutritional strategies that target underlying pathogenic mechanisms.

Manganese: An Essential Trace Mineral

Biochemical Functions

Manganese is required for the proper functioning of multiple enzymes. It acts as a cofactor for arginase (urea cycle), glutamine synthetase (glutamate metabolism), pyruvate carboxylase (gluconeogenesis), and most notably, manganese superoxide dismutase (MnSOD). MnSOD is the primary mitochondrial antioxidant enzyme that converts superoxide radicals into hydrogen peroxide, which is subsequently detoxified by catalase and glutathione peroxidase. Without adequate manganese, MnSOD activity declines, leaving mitochondria vulnerable to oxidative injury — a critical factor in diabetic neurons. Additionally, manganese is involved in the synthesis of glycosaminoglycans, which are essential for maintaining the structural integrity of connective tissues, including those supporting nerve sheaths.

Manganese Metabolism and Homeostasis

The body contains approximately 10–20 mg of manganese, with highest concentrations in bone, liver, kidney, and pancreas. Intestinal absorption is regulated by dietary levels and iron status; excess iron can inhibit manganese uptake. Excretion occurs primarily via bile, making liver function a key regulator of manganese levels. Deficiency is rare but can occur in individuals with malabsorption syndromes, genetic disorders such as hypermanganesemia, or those on parenteral nutrition without adequate manganese. Conversely, manganese toxicity (manganism) can arise from occupational inhalation or excessive supplementation, causing neurological symptoms resembling Parkinson’s disease. This narrow therapeutic window underscores the importance of achieving optimal rather than excessive intake.

Manganese and Insulin Secretion

Beyond its antioxidant role, manganese directly participates in pancreatic beta cell function. The mineral is a cofactor for enzymes involved in glucose-stimulated insulin secretion, and animal models of manganese deficiency show impaired insulin release and glucose intolerance. In human studies, serum manganese levels correlate positively with insulin sensitivity and beta cell function, though the directionality remains unclear. Some evidence suggests that manganese may also protect beta cells from oxidative injury, thereby preserving endogenous insulin production. This dual action — supporting both insulin secretion and nerve antioxidant defense — positions manganese as a uniquely relevant nutrient for diabetic neuropathy.

Research on Manganese and Nerve Health

Animal Studies

Animal models provide early evidence for manganese’s neuroprotective potential. In streptozotocin (STZ)-induced diabetic rats, supplementation with manganese (as manganese chloride) restored MnSOD activity in sciatic nerves, reduced markers of oxidative damage, and improved nerve conduction velocity compared to diabetic controls. Another study found that manganese treatment decreased apoptosis in dorsal root ganglion neurons exposed to high glucose, partly by upregulating the Nrf2 antioxidant pathway. These findings suggest that manganese may directly mitigate hyperglycemia-induced nerve injury. More recent work has shown that manganese supplementation also reduces inflammatory cytokine expression in peripheral nerves, indicating a broader anti-inflammatory effect that could complement its antioxidant actions.

Human Studies and Epidemiological Data

Human research is more limited but suggestive. A cross-sectional study in diabetic patients reported lower serum manganese levels in those with peripheral neuropathy compared to those without, after adjusting for age, diabetes duration, and HbA1c. However, causation cannot be inferred from observational data. A small randomized controlled trial investigated a combination supplement containing manganese, magnesium, zinc, and vitamin C in diabetic neuropathy patients. While the group receiving the supplement showed modest improvements in pain scores and nerve conduction, the contribution of manganese alone could not be isolated due to the multi-nutrient formulation. A 2021 meta-analysis of case-control studies found that serum manganese concentrations were significantly lower in type 2 diabetes patients versus controls, but heterogeneity among studies limited firm conclusions.

Research on manganese and diabetes is further complicated by the mineral’s dual role: some studies have linked high manganese exposure to increased diabetes risk and beta cell toxicity, particularly in occupationally exposed populations or those consuming water with elevated manganese levels. This underscores the importance of maintaining optimal — not excessive — manganese status, and suggests that U-shaped dose-response relationships may exist for both diabetes and neuropathy outcomes.

Mechanistic Insights from In Vitro Work

Cell culture studies have begun to unravel the molecular pathways through which manganese protects neurons. In Schwann cells exposed to high glucose, manganese supplementation reduces mitochondrial ROS production, preserves mitochondrial membrane potential, and prevents activation of the intrinsic apoptosis cascade. Manganese also enhances the expression of neurotrophic factors such as nerve growth factor and brain-derived neurotrophic factor, which are critical for nerve repair and regeneration. Furthermore, manganese modulates the activity of matrix metalloproteinases, enzymes involved in extracellular matrix remodeling that can become dysregulated in diabetic nerves and contribute to fibrosis and impaired regeneration.

Manganese and Blood Sugar Control

Involvement in Glucose Metabolism

Manganese participates in several steps of glucose metabolism. It activates pyruvate carboxylase, a key enzyme in gluconeogenesis, and modulates the activity of phosphoenolpyruvate carboxykinase. In animal models, manganese deficiency impairs glucose tolerance and reduces insulin secretion. Conversely, adequate manganese may support pancreatic beta cell function and improve peripheral insulin sensitivity. A meta-analysis of observational studies found lower serum manganese in type 2 diabetes patients compared to healthy controls, though the association remains to be confirmed in prospective trials. Notably, the relationship between manganese and glucose metabolism is bidirectional — hyperglycemia itself can alter manganese distribution and increase urinary manganese excretion, potentially creating a deficiency state that worsens metabolic control.

Potential to Reduce Hyperglycemic Damage

By improving glucose homeostasis, manganese could indirectly protect nerves from the toxic effects of sustained hyperglycemia. However, its primary role as an antioxidant cofactor likely exerts a more direct effect. Combining blood sugar management with enhanced antioxidant capacity may create a synergistic benefit for nerve integrity. Patients already on hypoglycemic medications should be aware that manganese can affect insulin sensitivity, and any significant changes in intake should be monitored alongside blood glucose levels. Some animal studies have shown that manganese supplementation enhances the effects of metformin on glycemic control, suggesting potential for drug-nutrient synergy that warrants further investigation.

Manganese and Diabetic Complications Beyond Neuropathy

The neuroprotective effects of manganese may extend to other diabetic complications driven by oxidative stress and mitochondrial dysfunction. Diabetic nephropathy, retinopathy, and cardiomyopathy all share pathogenic features with neuropathy, including ROS overproduction, inflammation, and microvascular damage. Preliminary evidence from rodent models suggests that manganese supplementation reduces markers of kidney injury and preserves glomerular filtration rate in diabetic rats. Similarly, manganese has been shown to protect retinal ganglion cells from hyperglycemia-induced apoptosis. While translating these findings to human clinical practice requires caution, the possibility that manganese status influences the progression of multiple diabetic complications adds weight to the argument for maintaining adequate intake.

Dietary Sources of Manganese

Foods Rich in Manganese

Manganese is widely available in plant-based foods. The richest sources include:

  • Nuts (especially hazelnuts, pecans, and walnuts) — a one-ounce serving of hazelnuts provides approximately 1.6 mg
  • Seeds (pumpkin seeds, flaxseeds, sunflower seeds)
  • Whole grains (oatmeal, brown rice, quinoa, barley) — cooked oatmeal offers about 0.6 mg per cup
  • Legumes (chickpeas, black beans, kidney beans) — a cup of cooked chickpeas contains roughly 0.9 mg
  • Leafy green vegetables (spinach, kale, Swiss chard) — cooked spinach provides about 0.8 mg per half cup
  • Tea (both black and green) — a cup of brewed black tea contributes 0.4–0.7 mg
  • Pineapple, blackberries, and other fruits — one cup of pineapple cubes delivers approximately 0.8 mg

A typical diet provides 2–5 mg of manganese per day, meeting the Adequate Intake (AI) of 2.3 mg for men and 1.8 mg for women. Factors that reduce absorption include dietary oxalates (in spinach, rhubarb), phytates (in grains and legumes), and high calcium or iron intake. Cooking can also affect manganese content; for instance, boiling may leach minerals into water, whereas steaming and roasting better preserve mineral content.

Bioavailability and Interactions

Manganese absorption ranges from 1–10% of dietary intake, with higher absorption rates when body stores are low. Vitamin C and organic acids (e.g., citric acid) can enhance absorption, while dietary fiber, tannins (in tea and coffee), and supplementation with high-dose zinc or calcium may reduce it. Individuals with iron deficiency experience increased manganese absorption due to upregulation of the divalent metal transporter 1 (DMT1), which transports both minerals. This interaction can be clinically relevant: diabetic patients with concomitant iron deficiency anemia — a common comorbidity — may absorb more manganese from their diet and supplements, potentially increasing toxicity risk if supplementation is not carefully monitored.

Supplementation Considerations

Manganese supplements are available as manganese gluconate, manganese sulfate, manganese amino acid chelates, and in multi-mineral formulas. Typical supplemental doses range from 5 to 20 mg per day, but toxicity can occur above 11 mg/day, according to the NIH Office of Dietary Supplements. The Tolerable Upper Intake Level (UL) for adults is 11 mg from both food and supplements. For diabetic nerve health, there is no established therapeutic dose, and self-prescribing without laboratory assessment of manganese status is not advisable. Chelated forms, such as manganese glycinate or bisglycinate, are often better absorbed and less likely to cause gastrointestinal upset compared to inorganic forms like manganese sulfate.

Risks of Toxicity

Chronic excessive manganese intake can lead to neurotoxicity, manifesting as tremors, bradykinesia, muscle rigidity, and psychiatric symptoms — a condition called manganism. This is of particular concern for individuals with compromised liver function, as manganese clearance is reduced. People with iron deficiency may absorb more manganese, increasing risk. Therefore, supplementation should only be considered under medical supervision, especially for patients with diabetes who may have concurrent liver steatosis or other complications. The onset of manganism is insidious and can be mistaken for Parkinson’s disease, making it essential to rule out manganese overload in patients presenting with extrapyramidal symptoms.

Monitoring and Laboratory Assessment

Before initiating manganese supplementation, clinicians should obtain baseline measurements of serum or plasma manganese, as well as iron status (serum ferritin, transferrin saturation), liver enzymes (ALT, AST, GGT), and complete blood count. Whole blood manganese is an alternative measure that reflects a longer exposure window. For patients on supplementation, periodic monitoring every 3–6 months is recommended to ensure levels remain within the reference range (typically 4–15 mcg/L for serum). Patients should be advised to track any new neurological symptoms and report them promptly. Supplementation should be discontinued if symptoms suggestive of manganese toxicity emerge or if laboratory values exceed the upper limit of normal.

Comparing Manganese to Other Neuroprotective Nutrients

Manganese is not the only nutrient studied for diabetic neuropathy. Other micronutrients with established roles include:

  • Vitamin B12: Essential for myelin synthesis and nerve repair; deficiency is common in metformin-treated patients and can mimic or exacerbate neuropathy symptoms.
  • Alpha-lipoic acid (ALA): A potent antioxidant that improves insulin sensitivity and reduces neuropathy symptoms in meta-analyses; it works synergistically with manganese by recycling other antioxidants like vitamin C and glutathione.
  • Magnesium: Involved in nerve conduction and glucose metabolism; deficiency linked to worsened neuropathy and increased oxidative stress.
  • Vitamin D: Plays a role in nerve growth factor signaling; low levels associate with painful neuropathy and reduced nerve regeneration capacity.
  • Zinc: Cofactor for SOD and other antioxidant enzymes; deficiency impairs immune function and wound healing in diabetic foot ulcers.

Each of these nutrients works through distinct pathways, and combined strategies may offer additive benefits. For example, manganese and zinc together support SOD activity in both mitochondrial (MnSOD) and cytosolic (CuZnSOD) compartments, providing comprehensive antioxidant coverage. However, high-dose manganese supplements should not replace a comprehensive approach that includes balanced nutrition, optimal glycemic control, and regular monitoring of vitamin and mineral status. A 2020 systematic review of nutritional interventions for diabetic neuropathy concluded that multi-nutrient formulations appear more effective than single-nutrient strategies, though the optimal composition remains undefined.

Practical Recommendations for Diabetic Patients

Prioritize Food First

The safest way to support manganese status is through diet. Emphasize whole foods: nuts, seeds, whole grains, and leafy greens. For example, a serving of cooked spinach (180 g) provides about 0.8 mg of manganese, while a handful of almonds (30 g) offers 0.5 mg. Combining these with vitamin C-rich foods can enhance absorption. It is also important to maintain adequate intake of copper, zinc, and iron, as these minerals interact with manganese metabolism through shared transport pathways. A diverse diet that includes a variety of manganese-rich foods can help ensure adequate intake without reaching levels associated with toxicity.

When to Consider Supplementation

Supplementation may be warranted in cases of confirmed deficiency, poor dietary intake (e.g., restrictive diets such as vegan or elimination diets that may be low in manganese), or malabsorption conditions (e.g., inflammatory bowel disease, gastric bypass surgery). Diabetic patients with neuropathy should first undergo laboratory evaluation of serum/plasma manganese, complete blood count, liver enzymes, and iron status. If supplementation is recommended, a low dose (e.g., 5 mg/day) in a chelated form may be used, with periodic monitoring to avoid cumulative overload. Always consult a healthcare professional before adding manganese supplements, especially if taking other antioxidants like ALA or vitamins B12 and D, as interactions are not well characterized. Pregnant and lactating women, individuals with liver disease, and those with occupational exposure to manganese fumes should exercise particular caution.

Integrating Manganese into a Broader Nerve Health Plan

Optimal nerve health requires more than any single nutrient. Patients should prioritize:

  • Glycemic control: Maintaining HbA1c below 7% (or individualized targets) reduces the metabolic triggers of neuropathy
  • Regular physical activity: Exercise improves nerve blood flow, reduces oxidative stress, and promotes neurotrophic factor release
  • Smoking cessation: Tobacco use worsens microvascular perfusion and amplifies oxidative damage
  • Foot care: Daily inspection and appropriate footwear prevent ulceration and infection
  • Comprehensive nutritional assessment: Screening for deficiencies in B vitamins, vitamin D, magnesium, zinc, and manganese should be part of routine diabetes care

When addressing dietary patterns, the Mediterranean diet, DASH diet, or a whole-food plant-based diet typically provide adequate manganese along with other protective nutrients. Recommending a broad dietary pattern rather than focusing on isolated nutrients reduces the risk of both deficiencies and excesses, and is supported by evidence from nutritional epidemiology.

Emerging Research and Future Directions

Manganese and the Gut-Nerve Axis

Recent research has highlighted the role of the gut microbiome in modulating manganese absorption and metabolism. Gut bacteria can influence manganese availability through fermentation of dietary fiber and production of short-chain fatty acids, which affect intestinal pH and mineral solubility. In diabetic patients, dysbiosis is common and may impair manganese uptake, potentially contributing to deficiency despite adequate dietary intake. Probiotic supplementation and prebiotic-rich foods might improve manganese status indirectly, though direct evidence in neuropathy patients is lacking. This area represents a frontier for future investigation.

Genetic Variability in Manganese Metabolism

Polymorphisms in genes encoding manganese transporters (e.g., SLC30A10, SLC39A8) and MnSOD (SOD2) can influence individual requirements and toxicity risk. For instance, the SOD2 Val16Ala polymorphism alters the efficiency of mitochondrial targeting and enzyme activity, with the Ala variant associated with lower MnSOD function and higher oxidative stress. Diabetic patients carrying this variant might derive greater benefit from optimized manganese status. Future clinical trials may incorporate genotyping to identify subgroups most likely to respond to manganese supplementation, moving toward personalized nutrition recommendations.

Conclusion

Manganese holds promise as a supportive nutrient for diabetic nerve health, primarily through its role as a cofactor for mitochondrial superoxide dismutase and its involvement in glucose metabolism and insulin secretion. While animal studies and epidemiological data suggest potential benefits for reducing oxidative stress and improving nerve function, human clinical trials specifically evaluating manganese supplementation for diabetic neuropathy are lacking. The existing evidence is insufficient to recommend routine supplementation, but maintaining adequate manganese through diet is a prudent and safe strategy. For patients with confirmed deficiency or those at high risk due to dietary restrictions or malabsorption, targeted supplementation under medical supervision may be considered, with careful dose selection and monitoring to avoid neurotoxicity.

Future research should focus on well-designed, randomized controlled trials that assess manganese status and supplementation in diabetic subjects with careful attention to dosage, duration, safety endpoints, and genetic modifiers. Such studies should also evaluate manganese as part of multi-nutrient protocols rather than in isolation, reflecting the complexity of nutritional interactions in neuropathy pathophysiology. In the meantime, patients and clinicians should view manganese as one component of a broad nutritional and lifestyle approach to nerve protection — a strategy grounded in sound science, delivered through whole foods, and monitored with appropriate laboratory assessment to ensure both efficacy and safety.

For more information on manganese and other minerals, visit the NIH Fact Sheet on Manganese, the NCBI Bookshelf summary of manganese biochemistry, and the American Diabetes Association resources on neuropathy management.